Holen Sie sich die Stockscreener-App
1.56
17.29%
0.23
Handel nachbörslich:
1.50
-0.06
-3.85%
Editas Medicine Inc Aktie (EDIT) Neueste Nachrichten
Leerink Partnrs Estimates Editas Medicine Q1 Earnings - MarketBeat
New Horizons in Biomedical CRISPR Gene Editing Market Exploring - openPR.com
Leerink Partnrs Predicts Editas Medicine Q3 Earnings - MarketBeat
Leber Congenital Amaurosis Market to Show Remarkable Growth - openPR.com
Raymond James Financial Inc. Takes $303,000 Position in Editas Medicine, Inc. (NASDAQ:EDIT) - MarketBeat
Genome Editing Market Growth 2025: Trends, Consumer Demand, - openPR.com
SEC Form PRE 14A filed by Editas Medicine Inc. - Quantisnow
Why Is Editas (EDIT) Down 37.1% Since Last Earnings Report? - Yahoo Finance
Editas Medicine: Do The Risks Outweigh The Rewards? (NASDAQ:EDIT) - Seeking Alpha
Zacks Research Raises Earnings Estimates for Editas Medicine - MarketBeat
Top 5 CRISPR Companies To Invest In (April 2025) - Securities.io
Editas Medicine (EDIT) Reports Q4 Loss, Misses Revenue Estimates - MSN
Editas Medicine stock hits 52-week low at $1.12 amid sharp decline - Investing.com
Editas Medicine stock hits 52-week low at $1.12 amid sharp decline By Investing.com - Investing.com South Africa
RNA Pioneer and Former Editas CEO Joins Codexis Board: Strategic Move for RNA Therapeutics Push - Stock Titan
Zacks Research Forecasts Editas Medicine FY2027 Earnings - MarketBeat
Gene Editing Market Detailed In New Research Report 2025-2032 | - openPR.com
Editas Medicine, Inc. (NASDAQ:EDIT) Looks Inexpensive After Falling 35% But Perhaps Not Attractive Enough - simplywall.st
Editas Medicine (NASDAQ:EDIT) Stock Price Crosses Below 50 Day Moving AverageWhat's Next? - MarketBeat
The Escalator: Bristol Myers Squibb, Editas Medicine, Takeda and more - Medical Marketing and Media
Editas Medicine, Inc. (NASDAQ:EDIT) Sees Large Drop in Short Interest - MarketBeat
Dyne names Editas’ Erick Lucera CFO - BioCentury
Gene Editing Market Demand, Growth and Future Scope 2025-2032 | - openPR
AstraZeneca deepens China investment; Editas loses CFO to Dyne - Yahoo Finance
BridgeBio, Editas finance chiefs depart; Former FDA No. 2 joins Recursion’s board - Endpoints News
Gene Editing Market Is Booming Worldwide 2025-2032 | CRISPR Therapeutics, Editas Medicine, Intellia Therapeutics - openPR
Editas Medicine appoints new CFO amid executive reshuffle By Investing.com - Investing.com Canada
Editas Medicine Announces CFO Transition - TipRanks
Editas Medicine appoints new CFO as Lucera steps down By Investing.com - Investing.com Australia
Editas Medicine appoints new CFO amid executive reshuffle - Investing.com
Editas Medicine Announces Chief Financial Officer Transition -March 20, 2025 at 04:45 pm EDT - Marketscreener.com
Editas Medicine appoints new CFO as Lucera steps down - Investing.com
Editas Medicine Announces Chief Financial Officer Transition - GlobeNewswire
Editas Medicine Promotes Finance VP to CFO: What Her 18-Year Track Record Means for EDIT - Stock Titan
Beta Thalassemia Market Predicted to See Upsurge Through 2034, - openPR
Monaco Asset Management SAM Takes $1.36 Million Position in Editas Medicine, Inc. (NASDAQ:EDIT) - MarketBeat
Editas Medicine, Inc. (NASDAQ:EDIT) Receives $6.83 Average Target Price from Brokerages - MarketBeat
Editas Medicine Reports Progress in Gene Editing - TipRanks
Gene Editing Market Future Business Opportunities 2025-2032 | - openPR
Here's Why Editas Medicine (NASDAQ:EDIT) Must Use Its Cash Wisely - Yahoo Finance
Editas Medicine’s SWOT analysis: gene editing firm pivots strategy amid stock volatility By Investing.com - Investing.com South Africa
Editas Medicine’s SWOT analysis: gene editing firm pivots strategy amid stock volatility - Investing.com
Editas Medicine, Inc. (NASDAQ:EDIT) Given Consensus Rating of “Hold” by Analysts - Defense World
0.92%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):